홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

아비라테론

Abiraterone

HCID 132971
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
154229-19-3
표준 SMILES
C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12
InChIKey
GZOSMCIZMLWJML-VJLLXTKPSA-N
분자식
C24H31NO
평균 분자량
349.5 g/mol
단동위원소 질량
349.24056461

개요

Abiraterone is a 3beta-sterol that is androsta-5,16-dien-3beta-ol substituted at position 17 by a 3-pyridyl group. Administered as the O-acetate, it is used for treatment of metastatic castrate-resistant prostate cancer. It has a role as an antineoplastic agent and an EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor. It is a 3beta-hydroxy-Delta(5)-steroid, a member of pyridines and a 3beta-sterol. It derives from a hydride of an androstane.

이름 및 식별자

우선 이름
Abiraterone
IUPAC
(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
현지명
아비라테론
영어명
Abiraterone
분자식
C24H31NO
분자량
349.52

이름 및 동의어

Abiraterone154229-19-3CB 7598CB-759817-(3-Pyridyl)androsta-5,16-dien-3beta-olAbirateronaabirateronumCB759817-(pyridin-3-yl)androsta-5,16-dien-3beta-ol(3beta)-17-(pyridin-3-yl)androsta-5,16-dien-3-olAndrosta-5,16-dien-3-ol, 17-(3-pyridinyl)-, (3beta)-(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
이름 더 보기
아비라테론(3S,8R,9S,10R,13S,14S)-10,13-diMethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-olAberration7-Keto Abiraterone Acetate(3β)-17-(3-Pyridinyl)androsta-5,16-dien-3-olCS-211AbironAbytron
G819A456D0NSC-741232CHEBI:68642DTXSID80879993(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta(a)phenanthren-3-olRefChem:57133L02BX03DTXCID501021626

물성

구조 계산 물성

XLogP
4.6
극성 표면적
33.1 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
2
회전 가능 결합 수
1
무거운 원자 수
26
형식 전하
0
복잡도
636

실험 및 물리화학적 성질

Drugs · 2건

Pharmaceuticals -> Metabolite of Abiraterone acetate

Pharmaceuticals -> Listed in ZINC15

Human DrugsHormones and antihormones
Endocrine DisruptorsPotential endocrine disrupting compound

물리화학적 성질

녹는점
227 · 227-228 °C(Solv: toluene (108-88-3))
끓는 점
500.2 · 500.2±50.0 °C(Predicted)
밀도
1.14 · 1.14±0.1 g/cm3(Predicted)
저장 조건
2 · 2-8°C
용해도
클로로포름(약간 용해됨), 메탄올(약간 용해됨)
물리적 상태
고체
산도 계수 (pKa)
14.71 · 14.71±0.70(Predicted)
색상
흰색에서 연한 노란색
InChIKey
GZOSMCIZMLWJML-DROLTIPTNA-N
SMILES
C[C@]12CC[C@]3([H])[C@]4(CC[C@H](O)CC4=CC[C@@]3([H])[C@]1([H])CC=C2C1=CN=CC=C1)C |&1:1,4,6,9,15,17,r|

화학적 성질

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H360 (57.1%): May damage fertility or the unborn child [Danger Reproductive toxicity]

P203, P260, P273, P280, P318, P319, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 7 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Regulatory InformationREACH registered substance: (1S,2R,5S,10R,11S,15S)-2,15-dimethyl-14-(pyridin-3-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵] heptadeca-7,13-dien-5-ol (EC: 810-941-6)
Hazard Classes and CategoriesRepr. 1B (57.1%)

독성 정보

Hepatotoxicity · 1건

Serum aminotransferase elevations occur in up to 13% of patients treated with abiraterone compared with 1% to 8% receiving placebo or a comparator drug, but the abnormalities are generally mild, transient and not associated with symptoms or jaundice. ALT elevations above 5 times the upper limit of normal (ULN) occur in 6% of abiraterone treated vs

Drug Induced Liver Injury · 4건

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Abiraterone

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

안전 데이터

신호 어
Warning
유해·위험 문구
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드 H302

화학 및 산업

약리 정보

ATC Code · 4건

L02BX03

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

L02BX03

Protein BindingAbiraterone is highly bound (>99%) to the human plasma proteins, albumin and alpha-1 acid glycoprotein.
Pharmacodynamics · 1건

_In vivo_, abiraterone acetate is rapidly hydrolyzed to abiraterone, which mediates its pharmacological actions. Abiraterone decreases serum testosterone and other androgens. A change in serum prostate-specific antigen (PSA) levels may be observed.

Mechanism of Action · 1건

17α-hydroxylase/C17,20-lyase (CYP17) is a key enzyme in androgen biosynthesis. It is primarily expressed in testicular, adrenal, and prostatic tumours. CYP17 catalyzes the 17α-hydroxylation of pregnenolone and progesterone to their 17α-hydroxy derivative, followed by subsequent cleavage of the C 20,21-acetyl group to yield dehydroepiandrosterone (DHEA) and androstenedione. DHEA and androstenedione are precursors of testosterone. Aberrant androgen levels and unregulated androgen receptor signalling have been implicated in the development and progression of various prostate cancers. Androgen-sensitive prostatic carcinoma responds to treatment that decreases androgen levels. Androgen deprivation therapies, such as treatment with GnRH agonists or orchiectomy, decrease androgen production in the testes but do not affect androgen production by the adrenals or in the tumour. Abiraterone inhibits CYP17 to block androgen production. Inhibition of CYP17 can also result in increased mineralocorticoid production by the adrenals.

Biological Half-LifeIn patients with mCRPC, the mean (± SD) terminal half-life of abiraterone in plasma is 12 (± 5) hours.
Metabolism/Metabolites · 2건

The conversion of abiraterone acetate to abiraterone, the active metabolite, is likely to be mediated by esterases, although specific esterases have not been identified. In human plasma, the two main circulating metabolites are abiraterone sulfate, which is formed by CYP3A4 and SULT2A1, and N-oxide abiraterone sulfate, which is formed by SULT2A1. These metabolites each account for about 43% of abiraterone exposure and are pharmacologically inactive.

관련 반응

14건
반응 기록 만들기
HRID 53180 반응식
HRID 53180생성물로
HRID 53189 반응식
HRID 53189생성물로
HRID 53190 반응식
HRID 53190반응물로
HRID 348776 반응식
HRID 348776생성물로
HRID 525309 반응식
HRID 525309반응물로
HRID 531211 반응식
HRID 531211반응물로
HRID 531212 반응식
HRID 531212반응물로
HRID 531213 반응식
HRID 531213반응물로
이전1 / 2 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트

데이터베이스 식별자

CAS
154229-19-3
PubChem CID
132971
DTXSID
DTXSID80879993
ChEMBL
CHEMBL254328
ChEBI
CHEBI:68642
UNII
G819A456D0
EC Number
810-941-6
Nikkaji
J617.457D

White Solid

Abiraterone has known human metabolites that include abiraterone sulfate.

FDA Pharmacological Classification · 6건

G819A456D0

ABIRATERONE

Mechanisms of Action [MoA] - Cytochrome P450 17A1 Inhibitors

Established Pharmacologic Class [EPC] - Cytochrome P450 17A1 Inhibitor

Mechanisms of Action [MoA] - Cytochrome P450 2D6 Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 2C8 Inhibitors

Absorption, Distribution and Excretion · 3건

Geometric mean (± SD) Cmax was 73 (± 44) ng/mL and AUC0-∞ was 373 (± 249) ng x hr/mL following a single dose of 500 mg abiraterone acetate in overnight-fasted healthy subjects. Dose proportionality was observed in single doses of abiraterone acetate ranging from 125 mg to 625 mg. A group of patients with mCRPC received a daily dose of 1,000 mg: at steady-state, the mean (± SD) Cmax was 226 (± 178) ng/mL and AUC was 993 (± 639) ng x hr/mL. Following oral administration of abiraterone acetate to patients with metastatic castration-resistant prostate cancer, the median Tmax was two hours. _In vivo_, abiraterone acetate is converted to abiraterone. In clinical studies of other abiraterone acetate formulations, abiraterone acetate plasma concentrations were below detectable levels (< 0.2 ng/mL) in > 99% of the analyzed samples. Systemic exposure to abiraterone is increased when abiraterone acetate is administered with food. Abiraterone Cmax was approximately 6.5-fold higher, and AUC0-∞ was 4.4-fold higher when a single dose of abiraterone acetate 500 mg was administered with a high-fat meal (56-60% fat, 900-1,000 calories) compared to overnight fasting in healthy subjects. Given the normal variation in the content and composition of meals, taking abiraterone with meals has the potential to result in increased and highly variable exposures.

Following oral administration of <sup>14</sup>C-abiraterone acetate, approximately 88% of the radioactive dose is recovered in feces: the major compounds present in feces are unchanged abiraterone acetate and abiraterone, accounting for approximately 55% and 22% of the administered dose, respectively. Approximately 5% of the dose is recovered in urine.

The mean (± SD) apparent steady-state volume of distribution is 19,669 (± 13,358) L.

응용 분야 · 2건

역사Abiraterone (brand name: Zytiga) is an anti-cancer drug developed by Centocor Ortho Biotech Inc. It was first approved by the FDA on 28 April 2011 for the treatment of advanced prostate cancer. In December 2012, the FDA expanded Zytiga's approved use to include treatment of men with advanced (metastatic) castration-resistant prostate cancer prior to chemotherapy. By February 2018, the FDA further approved Zytiga (abiraterone acetate) in combination with prednisone for the treatment of early metastatic prostate cancer.

용도Abiraterone, a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent pr ostate cancer.

상·하류 제품 정보

상류 원료

탄산나트륨(경회)Bis(triphenylphosphine)palladium(II) chloride수산화나트륨염산디에틸(옥시-피라질)보란

하류 제품

Abiraterone acetate

추가 설명

정의ChEBI: A 3beta-sterol that is androsta-5,16-dien-3beta-ol substituted at position 17 by a 3-pyridyl group. Administered as the O-acetate, it is used for treatment of metastatic castrate-resistant prostate cance .